Authors: NIAID Office of Communications Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis […]
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
Authors: By Jon Cohen, Kai KupferschmidtOct. 28, 2020 , 7:05 PM October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, […]
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
Authors: Beigel, et al. Remdesivir for the Treatment of COVID-19 – A Preliminary Report. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2007764 (2020). What The investigational antiviral remdesivir is superior to […]
Remdesivir for the Treatment of Covid-19 — Final Report
Authors: John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan […]
Severe covid-19 pneumonia: pathogenesis and clinical management
Authors: Amy H Attaway, assistant professor of medicine, associate director, COPD center1, Rachel G Scheraga, assistant professor of medicine1 2, Adarsh Bhimraj, head, section of neurological infections; staff, infectious diseases1, Michelle […]